Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Antidepressant Suicide Report May Have Been Suppressed – Sen. Grassley

This article was originally published in The Pink Sheet Daily

Executive Summary

Senate Finance Committee staffers are requesting a meeting with FDA to discuss the alleged suppression of an internal report on suicide-related events in children taking antidepressants.

You may also be interested in...



Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says

FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.

Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says

FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.

House Antidepressants Hearing To Include Six FDA Witnesses

House Energy & Commerce/Oversight Subcommittee hearing Sept. 23 will address FDA’s review of pediatric antidepressant data and is structured to pit the testimony of FDA Epidemiologist Andrew Mosholder against other agency officials.

Related Content

Topics

UsernamePublicRestriction

Register

PS058919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel